About

Indivior PLC (Indivior) is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence (the Indivior Business). Its treatment and pipeline focus is opioid use disorder, alcohol use disorder, overdose rescue... (more)

Financials

* ‍SUBLOCADE IS NOW AVAILABLE AS FIRST AND ONLY MONTHLY
INJECTABLE
BUPRENORPHINE IN U.S. TO TREAT PATIENTS WITH MODERATE TO SEVERE
OPIOID USE DISORDER​​
Source text for Eikon:
Further company coverage:

LONDON Britain's Indivior is launching a new weapon to fight the U.S. opioid crisis this month, but high hopes for its once-monthly injection were offset on Thursday by the need to set aside more cash for legal disputes.

LONDON Britain's Indivior is launching a new weapon to fight the U.S. opioid crisis this month, but high hopes for its once-monthly injection were offset on Thursday by the need to set aside more cash for legal disputes.

LONDON, Feb 15 Britain's Indivior is
launching a new weapon to fight the U.S. opioid crisis this
month, but high hopes for its once-monthly injection were offset
on Thursday by the need to set aside more cash for legal
disputes.

LONDON, Feb 15 Britain's Indivior,
which makes drugs to treat opioid addiction and plans to launch
a key new product this month, said on Thursday it had increased
provisions for investigative and antitrust litigation matters to
$438 million.

Related Topics:

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV. Learn more about Thomson Reuters products: